SK Biopharm has created a new drug development task force (TF) with SK Corporation.

COMPANY / Reporter Kim Jisun / 2023-03-27 03:15:25
This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology
사진= 연합뉴스 제공 

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] SK biopharmaceuticals has created a new drug development task force (TF) with SK Corporation, the holding company of SK Group. 

 

With a large number of key figures from SK and SK Biopharm in the TF, Choi Yoon-jung, head of SK biopharmaceuticals' strategic investment team, the eldest daughter of SK Group Chairman Choi Tae-won, reportedly joined the group.

According to the industry on the 24th, the two companies have recently set up such a TF to strengthen the development of new drugs in the pharmaceutical and bio sectors. However, as it is still in the early stages of TF formation, no specific development direction has been decided.

While SK CEO and Vice Chairman Jang Dong-hyun headed the TF, SK joined Kim Yeon-tae, head of the bio-investment center, and Cho Ah-ryeon, head of the bio-investment center group, while Lee Dong-hoon and Yoo Chang-ho, head of the strategic and investment division, joined SK biopharmaceuticals. On top of that, Choi's eldest daughter, Choi, is also known to participate.

TF plans to start work on the 27th.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Lotte Chilsung to Offer First-Ever Voluntary Retirement Program in 75 Years
Police Refer Former Doosan Bobcat Korea Executives to Prosecutors Over Bid-Rigging and Bribery Allegations
SK Group to Launch Early Year-End Executive Reshuffle; Major Layoffs Expected at SK Telecom
KT Accused of Concealing 2024 Malware Infection Affecting Subscriber Data; Government Probe Finds Security Failures Behind Micropayment Hacking
Korea’s National Pension Service Gains Strong Q3 Returns from U.S. Tech Stocks Amid Market Rally
뉴스댓글 >

SNS